FDA Inspection 1084076 — Roswell Park Cancer Institute Corporation. Div. of Pathology
The FDA completed an inspection of Roswell Park Cancer Institute Corporation. Div. of Pathology on March 1, 2019 in Buffalo, NY. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- March 1, 2019
- Fiscal Year
- 2019
- Product Type
- Biologics
- Project Area
- Blood and Blood Products
- Location
- Buffalo, NY (United States)